Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway

Table 3 Pre- and post-diagnosis NA-NSAID use and cause-specific survival following an ovarian cancer diagnosis: epithelial ovarian cancers diagnosed in Norway 2004–2018

Timing of exposure and exposure level	Deaths	Person-years	HR^a	95% CI
Pre-diagnosis
No NA-NSAIDs	1812	15,068	Ref.
NA-NSAIDs use	161	1230	1.10	0.93	-	1.30
Post-diagnosis, Baseline exposure
No NA-NSAIDs	1733	14,452	Ref.
NA-NSAIDs use	240	1846	1.09	0.92	-	1.29
Only post	185	1386	1.11	0.92	-	1.33
Pre and post	55	460	1.05	0.79	-	1.40
Post-diagnosis, Updated exposure
No NA-NSAIDs	1483	11,741	Ref.
Ever NA-NSAIDs	490	4563	1.13	1.00	-	1.28
Current NA-NSAIDs	96	944	0.92	0.74	-	1.14
Past NA-NSAIDs	394	3619	1.20	1.05	-	1.38
No NA-NSAIDs	1483	11,741	Ref.
DDD < median	252	2451	1.03	0.89	-	1.19
DDD ≥ median	238	2111	1.27	1.09	-	1.49

^aMultivariable models controlling for age at diagnosis (continuous), histology groups (; high grade serous, low grade serous, endometrioid, mucinous, clear cell, carcinosarcoma), stage (localized, regional, distant, missing), ethnicity (Norway, other Nordic, other), education (mandatory level, secondary, higher education, missing), marital status (single, married/partnered, widowed/separated/divorced), and use of other medications at baseline (medications indicated for cardiovascular disease, and statins and anti-diabetics)
Abbreviations: DDD = Defined Daily Dose; NSAIDs = non-steroidal anti-inflammatory drugs; NA-NSAIDs = non-aspirin NSAIDs

ISSN: 1471-2407